{"id":982700,"date":"2026-07-20T07:42:15","date_gmt":"2026-07-20T11:42:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asrs-2026-annual-meeting\/"},"modified":"2026-07-20T07:42:15","modified_gmt":"2026-07-20T11:42:15","slug":"harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asrs-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harrow-highlights-growing-clinical-evidence-supporting-iheezo-and-byooviz-at-asrs-2026-annual-meeting\/","title":{"rendered":"Harrow Highlights Growing Clinical Evidence Supporting IHEEZO\u00ae and BYOOVIZ\u00ae at ASRS 2026 Annual Meeting"},"content":{"rendered":"
\n

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO\u00ae<\/sup> (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ\u00ae<\/sup> (ranibizumab-nuna)i<\/sup>, an FDA-approved biosimilar referencing LUCENTISii<\/sup> (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow’s retina portfolio and reinforce Harrow\u2019s commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.<\/p>\n

\u201cASRS is one of the premier scientific meetings in retina, and we’re excited to share data that continues to strengthen the foundation supporting our growing retina franchise,\u201d said Mark L. Baum, Chief Executive Officer of Harrow. \u201cWe believe durable commercial success is built on strong clinical evidence, generated before FDA-approval, and then robust supportive data sets subsequently produced. These studies further expand the evidence supporting IHEEZO while adding to the growing body of real-world experience for BYOOVIZ, reflecting our long-term commitment to retina specialists and the patients they treat.\u201d<\/p>\n

One presentation highlighted interim findings from an investigator-initiated, prospective, randomized study of 150 patients comparing IHEEZO versus subconjunctival lidocaine. While these preliminary data represent an early look at the data, investigators observed encouraging trends toward less post-procedure pain, a better post-injection patient experience, and fewer ocular symptoms through 24 hours following intravitreal injection among patients treated with IHEEZO. Harrow believes these early findings provide an encouraging signal supporting further investigation in a larger patient population.<\/p>\n

Importantly, Harrow continues to enroll QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects that is being conducted under an active Investigational New Drug (IND) application. QUELL is designed to generate robust clinical evidence evaluating post-injection pain, patient experience, procedural performance, and safety in a substantially larger patient population, with topline data expected in the fourth quarter of 2026.<\/p>\n

Another real-world study retrospectively evaluated whether IHEEZO’s proprietary low-viscosity gel formulation interferes with antisepsis when used with chlorhexidine before intravitreal injection. Across nearly 20,000 injections, investigators observed no evidence of an increased endophthalmitis risk compared with a legacy tetracaine\/povidone-iodine preparation. Although retrospective and not intended to demonstrate statistical superiority, the findings provide further confidence that physicians can realize the patient-experience benefits of IHEEZO’s low-viscosity gel formulation without introducing additional procedural risk associated with antisepsis.<\/p>\n

\u201cThese studies help build the scientific foundation supporting IHEEZO,\u201d said Amir Shojaei, Chief Scientific Officer of Harrow. \u201cThe early interim randomized data suggest the potential to improve the patient experience, while the large real-world analysis provides reassuring evidence regarding procedural safety. We look forward to completing enrollment in QUELL, which we believe will provide the most comprehensive evaluation of IHEEZO in retina to date.\u201d<\/p>\n

Finally, Samsung Bioepis presented interim findings from a large-scale, real-world post-marketing surveillance study of BYOOVIZ. Full results from this study are being announced jointly with Samsung Bioepis today.<\/p>\n

\u201cBetween the continued expansion of the clinical evidence supporting IHEEZO, the recent launch of BYOOVIZ, and the ongoing growth of our retina franchise, we believe Harrow is increasingly well-positioned as a trusted long-term partner to retina specialists,\u201d Baum concluded. \u201cWe appreciated the opportunity to engage with physicians throughout ASRS and look forward to sharing additional updates later this year.\u201d<\/p>\n

\n IHEEZO\u00ae<\/sup> (chloroprocaine hydrochloride ophthalmic gel) 3%, for topical ophthalmic use<\/strong>\n <\/p>\n

\n INDICATIONS AND USAGE<\/strong>\u00a0<\/p>\n

IHEEZO is an ester anesthetic indicated for ocular surface anesthesia.\u00a0<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\u00a0<\/p>\n

\n CONTRAINDICATIONS<\/strong>\u00a0<\/p>\n